Qiyi Luo Ph.D

About team luoqiyi

Dr. Luo, born in 1962, was the chief technology officer and a member of the Greater China Executive Committee and Intercontinental Cardiac Rhythm Management Committee of the Company. Dr. Luo joined the Group in January 2003, and has been mainly responsible for the technology, and research and development of the Group. Dr. Luo was appointed as a non-executive director and the chairman of MicroPort CardioFlow Medtech Corporation (“CardioFlow”, a subsidiary of the Group listed on the Hong Kong Stock Exchange, stock code: 2160) in August 2019 and January 2020 respectively, and resigned from these positions in August 2023. From June 2019 to August 2023, Dr. Luo also served as a director of Shanghai MicroPort EP MedTech Co., Ltd. (an associate of the Group listed on the Science and Technology Board of Shanghai Stock Exchange, stock code: 688351).

Dr. Luo has over 32 years of experience in the medical device industry. He worked as the principal research and development engineer and a senior manufacturing/development engineer at Medtronic AVE Inc. from May 1995 to December 2002. From February 1991 to May 1995, he worked as a supervisor and an engineer of the angioplasty research and development team at Vas-Cath Inc., a subsidiary of C.R. Bard, Inc., a medical device manufacturing company listed on the New York Stock Exchange (ticker symbol: BCR).

Dr. Luo received his bachelor’s degree in applied science from Yunnan University of Technology (云南理工大学) in July 1983, his master’s degree in applied science from Queen’s University in Canada in December 1990 and his doctor’s degree in biomedical engineering from University of Shanghai for Science and Technology (上海理工大学) in March 2015. Dr. Luo has been the inventor or the co-inventor of over 300 patents in China, the United States, Japan and the European Union.